Journal for ImmunoTherapy of Cancer

POSTER PRESENTATION Open Access

Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment

Sadna Budhu[1], David Schaer[1*], Yongbiao Li[1], Alan Houghton[1], Samuel Silverstein[3], Taha Merghoub[1,2], Jedd Wolchok[1,2]

From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013

Regulatory T cells (Treg) play a role in suppression of anti-melanoma immunity; however, the exact mechanism is poorly understood. Through intravital two photon microscopy, we found that Pmel-1 effectors engage in cell-cell interactions with tumor resident Tregs. To determine if contact between Tregs and T effectors (Teff) hinders killing of tumor cells in vivo, we utilized ex-vivo three-dimensional collagen-fibrin gel cultures of B16 melanoma cells. Collagen-fibrin gel cultures recapitulated the in vivo suppression, rendering the dissociated tumor resistant to killing by in vitro activated antigen specific Teff. In vivo depletion of Tregs in foxp3-DTR mice prior to tumor excision reversed the suppression. Additionally, In vivo modulation of intra-tumor Tregs suppressive function by GITR ligation had a similar effect, leading to ex-vivo tumor killing. Using neutralizing antibodies, we found that blocking TGF-β reversed the suppression. In addition, soluble factors from collagen-fibrin gel tumors do not inhibit killing suggesting that suppression is contact or proximity dependent. The CD8 Teff recovered from these gels exhibit a decrease in Granzyme B expression and an increase in expression of T cell exhaustion marker PD-1. These findings support the conclusion that intra-tumor contact with Tregs during the effector phase of the immune response is responsible for inhibiting anti-melanoma immunity in a TGF-β dependent manner, elucidating a novel way to target intratumoral Tregs.

Authors' details
[1]Immunology, MSKCC, New York, NY, USA. [2]Medicine, MSKCC, New York, NY, USA. [3]Columbia University, New York, NY, USA.

Published: 7 November 2013

doi:10.1186/2051-1426-1-S1-P173
Cite this article as: Budhu *et al.*: Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment. *Journal for ImmunoTherapy of Cancer* 2013 **1**(Suppl 1): P173.

[1]Immunology, MSKCC, New York, NY, USA
Full list of author information is available at the end of the article